Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients With Mixed Solid Tumors (GO30103)

By sjmartinez • December 18, 2023

Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients With Mixed Solid Tumors (GO30103). J Clin Pharmacol. 2023 Dec 17. doi: 10.1002/jcph.2397. Epub ahead of print. PMID: 38105505.

Tags: Atezolizumab, Hematology/Oncology, PD-L1, Phase 1a/1b, Publications, TIGIT, Tiragolumab

Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation

Saco JD, Karin D, Patten JJ, Bachl S, Ching C, Kale N, Fan Y, Medina E, Naser Al Deen N, Champhekar A, Kaelin WG, Schulman[...]

Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance

Nishimura RN, Gera JF. Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance. Int J Mol Sci. 2026 Sep[...]

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J,[...]